AstraZeneca Pharma India Limited announced a 37% revenue growth for the quarter ended September 30, 2025, driven by strong performance in Oncology and Biopharmaceuticals. Revenue for Q2 2025-26 reached ₹5,590.9 million, and H1 2025-26 revenue totaled ₹10,854.0 million. The company also highlighted seven new approvals in H1, reinforcing its leadership across key therapy areas.
Financial Performance Overview
AstraZeneca Pharma India Limited reported a significant 37% revenue increase for Q2 2025-26. The company’s revenue for the quarter ending September 30, 2025, reached ₹5,590.9 million. Overall, H1 2025-26 revenue totaled ₹10,854.0 million. This growth reflects disciplined execution and strong momentum in key therapeutic areas.
Key Financial Highlights
Here is a summary of the company’s financial performance (in INR Mn):
Total revenue from Operations, Q2 2025: 5,590.9
Total revenue from Operations, H1 2025: 10,854.0
Total revenue from Operations, Q2 2024: 4,080.0
Total revenue from Operations, H1 2024: 7,955.2
Profit before exceptional item and tax, Q2 2025: 781.1
Profit before exceptional item and tax, H1 2025: 1531.7
Profit before exceptional item and tax, Q2 2024: 510.3
Profit before exceptional item and tax, H1 2024: 934.3
Profit after exceptional item and tax, Q2 2025: 542.2
Profit after exceptional item and tax, H1 2025: 1100.5
Profit after exceptional item and tax, Q2 2024: 384.3
Profit after exceptional item and tax, H1 2024: 266.4
Performance by Therapy Area
The company witnessed robust growth across its therapy areas:
Oncology, Q2 2025: 3,977.5
Oncology, H1 2025: 7,673.6
Biopharmaceuticals (CVRM, R&I and V&I), Q2 2025: 1,267.5
Biopharmaceuticals (CVRM, R&I and V&I), H1 2025: 2,457.5
Rare Disease, Q2 2025: 38.1
Rare Disease, H1 2025: 42.3
New Drug Approvals and Milestones
AstraZeneca highlighted several key regulatory approvals and milestones including:
- Durvalumab: Received approval for additional indications in endometrial cancer treatment.
- Launched Eculizumab for the treatment of atypical Haemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH).
- Osimertinib: Received approval for use in combination with chemotherapy for first-line treatment of NSCLC.
- Trastuzumab deruxtecan: Received approval for an additional indication in HER2-low and HER2-ultralow metastatic breast cancer patients.
- Osimertinib: Approval for monotherapy treatment of NSCLC.
- Benralizumab: Approval as an add-on treatment for EGPA.
Source: BSE
